Vir Biotechnology 거래 VIR

매도
 매수

VirBiotechnology 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

VirBiotechnology news

최신 뉴스

더 보기
Sophia Claire 2025 Sep 30, 01:20

Potential Government Shutdown Threatens Key US Economic Data Delays

Noah Lee 2025 Sep 29, 14:20

Trump's 100% Tariff on Foreign Films: Hollywood's Future at Stake?

Liam James 2025 Sep 29, 06:20

Buffett Indicator Hits Record High: Market Valuation Concerns

Ava Grace 2025 Sep 29, 04:20

US Allies in Asia Balk at Trump's Investment Demands: South Korea and Japan Reassess Pledges

Liam James 2025 Sep 29, 03:20

US Treasury Yields Navigate Fed Uncertainty, Government Shutdown Risk

Emma Rose 2025 Sep 29, 02:20

Netanyahu-Trump Meeting: A New Gaza Peace Plan on the Table

Ava Grace 2025 Sep 29, 01:20

Fed Chair Succession: Waller vs. Hassett - Economists' Wishes vs. Political Reality

Liam James 2025 Sep 28, 06:20

Trump Mocks Powell with AI Image Amidst Rate Cut Debate

정보

스프레드

0.06

스프레드(%)

1.0490 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 폐장

월요일

13:31 - 19:59

화요일

13:31-19:59

수요일

13:31-19:59

목요일

13:31-19:59

금요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

795991168

발행 주식 수

138916426

수익 날짜 (다음)

0000-00-00

배당수익률

배당락일

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

-4.01

이 상품에 대해 자세히 알아보기

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments

latest_education_articles

더 보기
Trustpilot